Plozasiran is an APOC3-directed siRNA approved for familial chylomicronemia syndrome. This page compares Plozasiran with Olezarsen (Tryngolza), another drug in this class.
Plozasiran Alternatives: How It Compares to Other APOC3 Inhibitors
Hipa.ai Research · Source: ClinicalTrials.gov / AACT · Last updated: AI-augmented data · 0/3 curated
Source: ClinicalTrials.gov via AACT · Hipa.ai, 2026-05-07Download chart as PNG
Olezarsen (Tryngolza) was approved in 2024, preceding Plozasiran's approval in 2025. Volanesorsen remains in Phase 3, approximately 1-2 years behind Plozasiran.
Quick comparison table
| Drug | Class | Approved indications | Dosing | Year approved | Lead pivotal endpoint | Annual cost (rough) |
|---|---|---|---|---|---|---|
| Plozasiran (Redemplo) | APOC3-directed siRNA | familial chylomicronemia syndrome | 25 mg subcutaneously once every 3 months | 2025 | — | $45k |
| Olezarsen (Tryngolza) | APOC3-directed antisense oligonucleotide | Familial chylomicronemia syndrome | 80 mg subcutaneously once monthly | 2024 | placebo-adjusted mean reduction in fasting triglycerides: 42.5% @ 6 months | $40k |
| Volanesorsen (Waylivra) | Apolipoprotein C-III (ApoC-III) inhibitor | — | 285 mg subcutaneously once weekly for 3 months, then 285 mg every 2 weeks | Pipeline | — | — |
Cost estimates are list-price approximations and do not reflect rebates, formulary tier, or out-of-pocket costs after benefits. The class-typical lead-pivotal endpoint here is Triglyceride % change; cells render each drug's actual pivotal endpoint, which may differ. The "Year approved" column shows the FDA approval year for familial chylomicronemia syndrome specifically — drugs approved for other indications first appear with their this-indication date, or as Pipeline if not yet approved for this indication. Cross-trial comparisons can mislead — head-to-head Phase-3 data (when present) is below.
Plozasiran vs Olezarsen (Tryngolza)
No head-to-head Phase-3 trial directly compares Plozasiran with Olezarsen.
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Pipeline alternatives
No investigational IL-17 or IL-17-related drugs in active Phase 3 development were provided in the data.
Choosing between Plozasiran and its alternatives
When considering APOC3 inhibitors, clinicians may evaluate Plozasiran, an APOC3-directed siRNA, for its distinct mechanism of action. This siRNA approach offers a different therapeutic strategy compared to antisense oligonucleotides such as Olezarsen (Tryngolza). While detailed efficacy and dosing profiles for Plozasiran are not presented here, its unique mechanism may inform treatment decisions for patients requiring APOC3 inhibition.
Conversely, Olezarsen (Tryngolza), an APOC3-directed antisense oligonucleotide, offers a well-defined profile for triglyceride reduction. Clinical data indicate a placebo-adjusted mean reduction in fasting triglycerides of 42.5% at 6 months with Olezarsen. The established dosing regimen for Olezarsen is 80 mg subcutaneously once monthly. This specific efficacy and dosing information may guide selection for patients where a predictable reduction in triglycerides and a monthly subcutaneous administration are key considerations. The differing mechanisms of action between siRNA and antisense oligonucleotides may also be a factor for specific patient subgroups.
This information is for educational purposes only and does not constitute medical advice; clinical decisions regarding patient care should always be made by a qualified prescriber.
Sources and methodology
Trial data was pulled from the ClinicalTrials.gov registry via the AACT relational mirror maintained by the Clinical Trials Transformation Initiative. AACT data freshness: .
Cross-trial comparison limitations:drugs without a direct head-to-head trial are compared using each drug's own pivotal trial. These trials enrolled different patient populations at different time points and used different statistical analysis sets. Cross-trial response-rate differences should not be interpreted as proof that one drug is more effective than another.
Related drug pages on Hipa.ai
Not medical advice. This page summarizes publicly-reported clinical trial data for informational purposes. Treatment decisions belong with a qualified prescribing clinician who knows your medical history. Drug approvals, dosing, and safety profiles change over time — always confirm with the current FDA prescribing information.
plozasiranplozasiran alternativesalternativescomparisonfamilial chylomicronemia syndromeapoc3-fcsplozasiran vs olezarsenplozasiran vs volanesorsen